Antibiotic Incentive “Wild Card” Profits Should Be Reinvested In R&D – IDSA

An Infectious Diseases Society of America report calls for creation of an independent panel to identify priority pathogens. Drugs developed for these strains should be eligible for intellectual property and financial incentives, the group suggests.